drugset / Trial / NCT06139211
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with advanced solid tumors. The Recommended dose for phase II trial （RP2D） will be determined based on the safety, tolerability, pharmacokinetics and efficacy.
Timeline
- Start
- 2024-01-03
- Primary completion
- 2025-11-01
- Completion
- 2026-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Gemcitabine | Small molecule | — | Intravenous |
| Subject | Irinotecan | Small molecule | — | Intravenous |
| Subject | JS015 | Unknown | — | Intravenous |
| Subject | Oxaliplatin | Small molecule | — | Intravenous |
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |
| Subject | fluorouracil | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |